Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MAINTRAC-Auto

Financiado

Cerrado

MAINTRAC Auto Automatization and validation of a liquid biopsy assay Maintrac...

MAINTRAC Auto Automatization and validation of a liquid biopsy assay Maintrac AUTO CTC analyser for predictive real time monitoring and success control of solid tumor cancer therapy Worldwide cancer is one of the leading causes of death and the need for more effective therapies is crucial. New precision diagnostics can identify and characterize the disease to individualize the therapy throughout the course of... ver más

31/08/2016

SIMFO

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

SIMFO SPEZIELLE IMMUNOLOGIE FORSCHUNG UND ENT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-08-31

PHC-12-2015-1: Clinical research for the validatio...

I+D

Cerrada hace 9 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

SIMFO

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CTCapture_2.0 Advanced platform for profiling of therapeutic targets and f... 150K€ Cerrado

NO-META Feasibility study of a NOvel METAbolic liquid biopsy for can... 71K€ Cerrado

PID2020-120306RB-I00 INTEGRAL STAGING, PROGNOSTIC AND DIAGNOSTIC OF CANCER IN LIQ... 184K€ Cerrado

DeteCTCs The first multi cancer liquid biopsy test for detection of e... 3M€ Cerrado

LIMA Liquid biopsies and Imaging for improved cancer care 6M€ Cerrado

CanDo A CANcer Development mOnitor 5M€ Cerrado

Duración del proyecto: 6 meses Fecha Inicio: 2016-02-12
Fecha Fin: 2016-08-31

Líder del proyecto

SIMFO SPEZIELLE IMMUNOLOGIE FORSCHUNG UND ENT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Worldwide cancer is one of the leading causes of death and the need for more effective therapies is crucial. New precision diagnostics can identify and characterize the disease to individualize the therapy throughout the course of cancer, like our clinically approved Maintrac-CTC assay. Maintrac-CTC can track circulating tumor cells (CTCs) even in primary cancer patients to estimate prognosis and diagnose relapse well before clinical symptoms arise. Meanwhile a fully automated Maintrac AUTO analyser was established and offers a standardized state-of-art biomarker system for direct and better monitoring of disease progression and effectiveness i.e. of the maintenance therapy in breast cancer. We aim to drastically increase both effectiveness (selection of treatment most adequately for individual cancer type and phase) and efficiency (early indicator for the response level to an initial therapy) to avoid ineffective therapies, savings cost for the health care system and substantially reducing patient suffering. The objectives of the innovation project are to achieve series-production readiness and launch the system commercially with the best business model. We aim for acceptance of Maintrac CTC assays by oncology specialists through clinical validation and to achieve reimbursement by public authorities for upscaling and market penetration. In phase 1 we will show equivalence of the automatic system to the established manual method and meet regulatory requirements. In addition business opportunities and appropriate sales model will be evaluated. Forecasts for overall CTC biomarker market estimate a big market with a high demand for innovative products with expected revenue potential of US$ 12bn in 2020. Due to the obvious relevance of cancer diseases for patients, their families as well as economic implications, Maintrac will have an important impact on future cancer disease management.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores